Precision BioSciences, Inc. (DTIL)
Largest Insider Buys in Sector
DTIL Stock Price History Chart
DTIL Stock Performance
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Insider Activity of Precision BioSciences, Inc.
Over the last 12 months, insiders at Precision BioSciences, Inc. have bought $43,200 and sold $158,862 worth of Precision BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Precision BioSciences, Inc. have bought $70,550 and sold $1.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kelly John Alexander (Chief Financial Officer) — $43,200.
The last purchase of 90,000 shares for transaction amount of $43,200 was made by Kelly John Alexander (Chief Financial Officer) on 2023‑08‑18.
List of Insider Buy and Sell Transactions, Precision BioSciences, Inc.
| 2024-06-10 | Sale | SMITH J. JEFFERSON | Chief Research Officer | 50 0.0007% | $11.79 | $590 | -13.98% | |
| 2024-06-10 | Sale | Scimeca Dario | General Counsel and Secretary | 93 0.0013% | $11.79 | $1,096 | -13.98% | |
| 2024-05-02 | Sale | SMITH J. JEFFERSON | Chief Research Officer | 154 0.0021% | $10.32 | $1,589 | +9.96% | |
| 2024-05-02 | Sale | Amoroso Michael | President and CEO | 1,526 0.021% | $10.32 | $15,748 | +9.96% | |
| 2024-05-02 | Sale | Scimeca Dario | General Counsel and Secretary | 272 0.0037% | $10.32 | $2,807 | +9.96% | |
| 2024-05-02 | Sale | List Alan | Chief Medical Officer | 290 0.004% | $10.32 | $2,993 | +9.96% | |
| 2024-05-01 | Sale | Scimeca Dario | General Counsel and Secretary | 918 – | $0 | $0 | +12.98% | |
| 2024-04-30 | Sale | List Alan | Chief Medical Officer | 238 0.0033% | $10.03 | $2,386 | +13.20% | |
| 2024-01-23 | Sale | SMITH J. JEFFERSON | Chief Research Officer | 28,000 0.0231% | $0.37 | $10,360 | +3095.31% | |
| 2024-01-22 | Sale | Amoroso Michael | President and CEO | 137,390 0.1111% | $0.36 | $49,460 | +3089.66% | |
| 2024-01-22 | Sale | Scimeca Dario | General Counsel and Secretary | 21,287 0.0172% | $0.36 | $7,663 | +3089.66% | |
| 2024-01-22 | Sale | List Alan | Chief Medical Officer | 21,526 0.0174% | $0.36 | $7,749 | +3089.66% | |
| 2023-11-03 | Sale | Amoroso Michael | President and CEO | 125,025 0.1021% | $0.40 | $50,010 | +2338.91% | |
| 2023-11-03 | Sale | Scimeca Dario | General Counsel and Secretary | 16,023 0.0131% | $0.40 | $6,409 | +2338.91% | |
| 2023-08-18 | Kelly John Alexander | Chief Financial Officer | 90,000 0.0791% | $0.48 | $43,200 | -9.10% | ||
| 2023-06-08 | Sale | Scimeca Dario | General Counsel and Secretary | 13,361 0.0119% | $0.75 | $10,021 | -30.52% | |
| 2023-04-27 | Sale | List Alan | Chief Medical Officer | 7,771 0.0067% | $0.79 | $6,139 | -35.85% | |
| 2023-03-22 | Sale | Amoroso Michael | President and CEO | 46,999 0.0438% | $0.82 | $38,539 | -33.50% | |
| 2023-03-17 | Kelly John Alexander | Chief Financial Officer | 20,000 0.0178% | $0.86 | $17,200 | -39.54% | ||
| 2023-03-06 | Sale | Scimeca Dario | General Counsel and Secretary | 12,172 0.0109% | $1.07 | $13,024 | -50.84% |
Insider Historical Profitability
| SMITH J. JEFFERSON | Chief Research Officer | 68559 1.63% | $9.67 | 0 | 3 | |
| Kelly John Alexander | Chief Financial Officer | 383340 0.3144% | $9.67 | 6 | 0 | <0.0001% |
| Amoroso Michael | President and CEO | 13772 0.2924% | $9.67 | 0 | 5 | |
| Scimeca Dario | General Counsel and Secretary | 6721 0.1239% | $9.67 | 0 | 8 | |
| List Alan | Chief Medical Officer | 4488 0.0779% | $9.67 | 0 | 6 | |
| JANTZ DEREK | Chief Scientific Officer | 4055174 3.3261% | $9.67 | 0 | 17 | |
| FMR LLC | 3738248 3.0662% | $9.67 | 1 | 0 | <0.0001% | |
| KANE MATTHEW R. | President and CEO | 2013597 1.6516% | $9.67 | 0 | 15 | |
| YAO TONY DUNG LING | director | 158003 0.1296% | $9.67 | 1 | 0 | <0.0001% |
| THOMSON DAVID S. | Chief Operating Officer | 111513 0.0915% | $9.67 | 0 | 7 | |
| venBio Global Strategic Fund, L.P. | director | 50000 0.041% | $9.67 | 1 | 0 | <0.0001% |
| Heery Christopher | Chief Medical Officer | 2485 0.002% | $9.67 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Tang Capital Management, LLC | $7.99M | 8.51 | 589,569 | -82.66% | -$38.11M | 0.03 | |
| Janus Henderson | $7.74M | 8.27 | 573,052 | New | +$7.74M | <0.01 | |
| Perceptive Advisors | $6.52M | 6.94 | 480,483 | New | +$6.52M | <0.01 | |
| Spyglass Capital Management LLC | $5.23M | 5.57 | 385,440 | New | +$5.23M | 3.92 | |
| The Vanguard Group | $3.54M | 3.77 | 260,831 | -94.51% | -$60.94M | <0.0001 | |
| Alyeska Investment Group L P | $3.39M | 3.61 | 250,000 | New | +$3.39M | 0.02 | |
| Acadian Asset Management | $1.55M | 1.65 | 114,272 | -96.58% | -$43.75M | 0.01 | |
| Renaissance Technologies | $1.35M | 1.44 | 99,498 | -96.16% | -$33.78M | <0.01 | |
| Citadel Advisors LLC | $1.32M | 1.41 | 97,275 | -97.19% | -$45.68M | <0.01 | |
| Moloney Securities Asset Management Llc | $734,938.00 | 0.78 | 54,199 | -93.91% | -$11.34M | 0.12 | |
| Stifel | $540,650.00 | 0.58 | 39,871 | -97.42% | -$20.42M | <0.01 | |
| Geode Capital Management | $404,767.00 | 0.43 | 29,843 | -96.67% | -$11.74M | <0.0001 | |
| Bank of America | $385,280.00 | 0.41 | 28,413 | -96.7% | -$11.29M | <0.0001 | |
| BlackRock | $358,011.00 | 0.38 | 26,402 | -97.64% | -$14.82M | <0.0001 | |
| Tejara Capital Ltd | $335,841.00 | 0.36 | 24,767 | -96.67% | -$9.74M | 0.11 | |
| Blue Owl Capital Holdings Lp | $274,183.00 | 0.29 | 20,220 | -96.67% | -$7.95M | 0.05 | |
| Ci Private Wealth Llc | $161,106.00 | 0.17 | 11,881 | -94.78% | -$2.92M | <0.0001 | |
| Morgan Stanley | $159,452.00 | 0.17 | 11,759 | -96.48% | -$4.37M | <0.0001 | |
| Ubs Oconnor Llc | $156,564.00 | 0.17 | 11,546 | -95.15% | -$3.07M | 0.01 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $153,676.00 | 0.16 | 11,333 | New | +$153,676.00 | <0.01 | |
| Gsa Capital Partners Llp | $137,000.00 | 0.15 | 10,067 | New | +$137,000.00 | 0.01 | |
| Amundi | $91,345.00 | 0.12 | 8,521 | -96.67% | -$2.65M | <0.0001 | |
| JPMorgan Chase | $115,476.00 | 0.12 | 8,516 | -96.49% | -$3.18M | <0.0001 | |
| Allworth Financial Lp | $64,668.00 | 0.07 | 4,769 | -96.67% | -$1.88M | <0.0001 | |
| Vivo Capital | $63,395.00 | 0.07 | 4,675 | -96.67% | -$1.84M | 0.01 | |
| Barclays | $39,000.00 | 0.04 | 2,873 | -98.66% | -$2.87M | <0.0001 | |
| Advisor Group Holdings Inc | $25,695.00 | 0.03 | 1,895 | -95.77% | -$581,168.02 | <0.0001 | |
| Wells Fargo | $11,674.00 | 0.01 | 861 | -88.86% | -$93,107.27 | <0.0001 | |
| Tower Research Capital | $5,275.00 | 0.01 | 389 | New | +$5,275.00 | <0.0001 | |
| Zurich Cantonal Bank | $4,787.00 | 0.01 | 353 | -96.77% | -$143,243.86 | <0.0001 | |
| UBS | $2,793.00 | <0.01 | 206 | -99.77% | -$1.2M | <0.0001 | |
| Toth Financial Advisory Corp | $1,356.00 | <0.01 | 100 | New | +$1,356.00 | <0.0001 | |
| Newedge Advisors Llc | $644.00 | <0.01 | 48 | -98.2% | -$35,084.58 | <0.0001 | |
| Fidelity Investments | $27.00 | <0.01 | 2 | New | +$27.00 | <0.0001 | |
| Investors Research Corp | $108.00 | <0.01 | 8 | -96.8% | -$3,267.00 | <0.0001 | |
| Citigroup | $14.00 | <0.01 | 1 | -100% | -$653,044.00 | <0.0001 | |
| Ameliora Wealth Management Ltd | $447.00 | <0.01 | 33 | -96.7% | -$13,098.45 | <0.0001 | |
| Tsfg Llc | $0 | <0.01 | 3 | -97% | -$0 | <0.0001 | |
| Qube Research & Technologies | $68.00 | <0.01 | 5 | -98.05% | -$3,413.60 | <0.0001 | |
| GPS Wealth Strategies Group LLC | $14.00 | <0.01 | 1 | New | +$14.00 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 9 | -93.75% | -$0 | <0.0001 |